Basilea Pharmaceutica AG (SWX:BSLN)
47.30
+1.15 (2.49%)
Sep 30, 2025, 5:31 PM CET
Basilea Pharmaceutica AG Revenue
Basilea Pharmaceutica AG had revenue of 103.96M CHF in the half year ending June 30, 2025, with 22.44% growth. This brings the company's revenue in the last twelve months to 236.21M, up 58.51% year-over-year. In the year 2024, Basilea Pharmaceutica AG had annual revenue of 208.54M with 32.30% growth.
Revenue (ttm)
236.21M
Revenue Growth
+58.51%
P/S Ratio
2.46
Revenue / Employee
1.31M
Employees
164
Market Cap
581.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Basilea Pharmaceutica AG News
- 5 days ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire
- 14 days ago - Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 - GlobeNewsWire
- 6 weeks ago - Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - Basilea Pharmaceutica AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 weeks ago - Basilea Pharmaceutica AG GAAP EPS of CHF 1.26, revenue of CHF 104M; updates FY outlook - Seeking Alpha
- 6 weeks ago - Basilea on track with strong 2025 half-year results - GlobeNewsWire
- 6 weeks ago - Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic - GlobeNewsWire
- 5 months ago - Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica) - GlobeNewsWire